MedPath

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

Phase 3
Terminated
Conditions
Pulmonary Hypertension
Pulmonary Fibrosis
Interventions
Combination Product: INOpulse®
Combination Product: Open Label Extension
Combination Product: Placebo
Registration Number
NCT03267108
Lead Sponsor
Bellerophon Pulse Technologies
Brief Summary

A randomized, double-blind, placebo-controlled dose escalation and verification study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy (Part 1 and Part 2) - REBUILD

Detailed Description

This is a Phase 3, randomized, double-blind, placebo-controlled dose escalation and verification clinical study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy (Part 1 and Part 2) - REBUILD

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
145
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Inhaled Nitric Oxide (iNO)INOpulse®Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
Open Label ExtensionOpen Label ExtensionPulsed inhaled iNO 45 mcg/kg IBW/hr
PlaceboPlaceboPulsed inhaled N2, 99.999% gas
Primary Outcome Measures
NameTimeMethod
Change in Moderate to Vigorous Physical Activity (MVPA) as Measured by ActigraphyBaseline to Month 4

Part 1 - Blinded Treatment Period

Adverse Events and Serious Adverse Events with Long Term INOpulse TherapyBaseline to Month 4

Part 2 - Open Label Extension (OLE)

Secondary Outcome Measures
NameTimeMethod
Time to Clinical ImprovementBaseline to Month 4

Part 1 Blinded Treatment Period

Time to Clinical WorseningBaseline to Month 4

Part 1 - Blinded Treatment Period

Change in St. George Respiratory Questionnaire (SGRQ) - Activity, Impacts & TotalBaseline to Month 4

Part 1 Blinded Treatment Period: SGRQ is a tool for assessing quality of life that has previously been validated for the use with patients with interstitial lung disease. It is a responsive tool that has three domains: symptoms, activity and impact (on daily life)

Time to Clinical DeteriorationBaseline to Month 4

Part 1 Blinded Treatment Period

Change in Overall Activity as Measured by ActigraphyBaseline to M4

Part 1 - Blinded Treatment Period

Change in University of California San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)Baseline to Month 4

Part 1 Blinded Treatment Period: The UCSD SOBQ is a 24-item questionnaire developed to measure breathlessness associated with activities of daily living, on a scale between zero and five where 0 is not at all breathless and 5 is maximally breathless or too breathless to do the activity. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).

Change in 6 Minute Walk DistanceBaseline to Month 4

Part 1 Blinded Treatment Period

Trial Locations

Locations (64)

Stanford University Medical Center

🇺🇸

Stanford, California, United States

Amicis Research

🇺🇸

Northridge, California, United States

Mount Sinai Hospital

🇺🇸

New York, New York, United States

Georgetown University

🇺🇸

Washington, District of Columbia, United States

Avanza Medical Research Center

🇺🇸

Pensacola, Florida, United States

Cleveland Clinic

🇺🇸

Weston, Florida, United States

NYU Langone

🇺🇸

New York, New York, United States

Weill Cornell Medical Center

🇺🇸

New York, New York, United States

University of British Columbia

🇨🇦

Vancouver, British Columbia, Canada

Atlantic Health Respiratory Institute

🇺🇸

Summit, New Jersey, United States

Inova Heart and Vascular Institute Advanced Lung Disease Clinic

🇺🇸

Falls Church, Virginia, United States

University of California San Francisco

🇺🇸

Fresno, California, United States

University of California

🇺🇸

Los Angeles, California, United States

UT Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

Northside Hospital

🇺🇸

Atlanta, Georgia, United States

Loyola University

🇺🇸

Maywood, Illinois, United States

Stony Brook University Hospital

🇺🇸

Stony Brook, New York, United States

Pulmonix, LLC/LeBauer Cone Health

🇺🇸

Greensboro, North Carolina, United States

Thomas Jefferson University Korman Respiratory Institute

🇺🇸

Philadelphia, Pennsylvania, United States

Temple University

🇺🇸

Philadelphia, Pennsylvania, United States

Queen's University/Hotel Dieu Hospital

🇨🇦

Kingston, Ontario, Canada

Johns Hopkins Hospital

🇺🇸

Baltimore, Maryland, United States

Northwestern

🇺🇸

Chicago, Illinois, United States

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

University Hospitals

🇺🇸

Cleveland, Ohio, United States

University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

University of Miami

🇺🇸

Miami, Florida, United States

Ascension St. Vincent Hospital

🇺🇸

Indianapolis, Indiana, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

University of Utah Health Sciences

🇺🇸

Salt Lake City, Utah, United States

Banner - University Medical Center Arizona

🇺🇸

Phoenix, Arizona, United States

Arizona Pulmonary Specialists, Ltd.

🇺🇸

Phoenix, Arizona, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

The Ohio State University

🇺🇸

Columbus, Ohio, United States

Piedmont Healthcare

🇺🇸

Austell, Georgia, United States

North Shore University Hospital

🇺🇸

Evanston, Illinois, United States

University of Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

Baylor University Medical Center

🇺🇸

Dallas, Texas, United States

Southern Illinois University

🇺🇸

Springfield, Illinois, United States

University of Alabama

🇺🇸

Birmingham, Alabama, United States

National Jewish

🇺🇸

Denver, Colorado, United States

Creighton University

🇺🇸

Omaha, Nebraska, United States

The Oregon Clinic

🇺🇸

Portland, Oregon, United States

UC Denver Anschutz Medical Center

🇺🇸

Aurora, Colorado, United States

University of California Davis Health

🇺🇸

Sacramento, California, United States

University of South Florida

🇺🇸

Tampa, Florida, United States

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

Paloma Medical Group

🇺🇸

Paloma, California, United States

St. Francis Sleep Allergy and Lung Institute

🇺🇸

Clearwater, Florida, United States

Advanced Pulmonary Research Institute

🇺🇸

Loxahatchee Groves, Florida, United States

The Lung Research Center, LLC

🇺🇸

Chesterfield, Missouri, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

AnMed Health

🇺🇸

Anderson, South Carolina, United States

Metroplex Pulmonary and Sleep

🇺🇸

McKinney, Texas, United States

University of Washington Medical Center

🇺🇸

Seattle, Washington, United States

London Health Sciences Centre

🇨🇦

London, Ontario, Canada

Norton Pulmonary Specialists

🇺🇸

Louisville, Kentucky, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

The University of North Carolina at Chapel Hill Marsico Clinical Research Center

🇺🇸

Chapel Hill, North Carolina, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Pulmonary Associates of Richmond

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath